Health utility of type 2 diabetes patients using basal insulin in China: results from the BEYOND II study-Reference-Cited by-同舟云学术

Health utility of type 2 diabetes patients using basal insulin in China: results from the BEYOND II study

Published:2020-10-17 Issue:3 Volume:58 Page:329-339
ISSN:0940-5429
Container-title:Acta Diabetologica
language:en
Short-container-title:Acta Diabetol

Author:

Li Chaoyun,Zhou HuiJun,Wang Pei^ORCID

Funder

Sanofi China

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology,General Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00592-020-01618-1.pdf

Reference31 articles.

1. Federation ID (2019) IDF DIABETES ATLAS 9th edition 2019. Available at: https://diabetesatlas.org/data/en/. Accessed May 16 2020

2. Xu Y, Wang L, He J et al (2013) Prevalence and control of diabetes in Chinese adults. JAMA 310:948–959

3. Funnell MM (2008) Quality of life and insulin therapy in type 2 diabetes mellitus. Insulin 3:31–36

4. Gao LL, Ji LN, Lu JM et al (2014) Current status of blood glucose control and treatment of type 2 diabetes in China 2009–2012. Chin J Diabetes 22:594–598

5. Cai X, Shi L, Yang W et al (2019) Cost-effectiveness analysis of dapagliflozin treatment versus metformin treatment in Chinese population with type 2 diabetes. J Med Econ 22:336–343

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Health state utility values ranges across varying stages and severity of type 2 diabetes-related complications: A systematic review;PLOS ONE;2024-04-04

2. Evaluating the long-term cost-effectiveness of fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus other treatment regimens in the chinese type 2 diabetes patients;Diabetology & Metabolic Syndrome;2023-08-19

3. A Cost-effectiveness Analysis of iGlarLixi Versus IDegAsp and Appropriate Price Exploration of iGlarLixi for Type 2 Diabetes Mellitus Patients in China;Clinical Drug Investigation;2023-03-21

4. Cost–Effectiveness Analysis of Dapagliflozin Plus Standard Treatment for Patients With Type 2 Diabetes and High Risk of Cardiovascular Disease in China;Frontiers in Public Health;2022-07-13

5. Intravenous iron for the treatment of iron deficiency anemia in China: a patient-level simulation model and cost-utility analysis comparing ferric derisomaltose with iron sucrose;Journal of Medical Economics;2022-05-04